Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Mar 3;139(9):1266-1267.
doi: 10.1182/blood.2021014066.

CAR T cells and autologous transplantation can coexist for DLBCL

Premal D Lulla  1
Affiliations
Editorial

CAR T cells and autologous transplantation can coexist for DLBCL

Premal D Lulla. Blood. .

Erratum in

No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: P.D.L. reports advisory board participation for Karyopharm.

Figures

None
Shadman et al show that progression-free survival (PFS) with ASCT (52% at 2 years) and CAR T cells (42% at 2 years) are comparable (P = .1) for patients with DLBCL in PR after salvage chemotherapy. Multivariable regression and propensity risk matching confirm these trends, thus indicating both cell therapies are viable options for such patients. In this picture, ASCT is represented by an autorickshaw, fondly known as an autos in parts of Southeast Asia, while CAR T cells are represented by a car. Both modes of transportation coexist in many parts of the world.
See this image and copyright information in PMC

Comment on

References

    1. Shadman M, Pasquini MC, Ahn KW, et al. Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission. Blood. 2022;139(9): 1330-1339. - PMC - PubMed
    1. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333(23):1540-1545. - PubMed
    1. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531-2544. - PMC - PubMed
    1. Schuster SJ, Bishop MR, Tam CS, et al. ; JULIET Investigators . Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45-56. - PubMed
    1. Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839-852. - PubMed

Substances